Education
About Us
Working with TipRanks
Follow Us
Mark Eisner Insider Profile
4 Followers
Mark Eisner, EVP, Chief Medical Officer at FibroGen, holds 104.62K shares in Vir Biotechnology (Ticker: VIR), holds 159.92K shares in FibroGen (Ticker: FGEN).
Mark Eisner FibroGen (FGEN)EVP, Chief Medical Officer
FibroGen (FGEN)
EVP, Chief Medical Officer
Ranked #2,723 out of 102,971 Corporate Insiders
Profitable Transactions
6 out of 6 Profitable Transactions
Average Return
+80.40%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Mark Eisner holds in companies
Most Profitable Insider Trade
The most profitable trade made by Mark Eisner
Mark Eisner's Trading History
FibroGen
Sep 08, 2023
EVP, Chief Medical Officer
Uninformative Sell
1.79K
$1.52M
Vir Biotechnology
Jul 17, 2025
EVP and Chief Medical Officer
Uninformative Sell
19.62K
$472.87K
List of latest transactions for each holding click on a transaction to see Mark Eisner's performance on stock
You May Also Like
Mark Eisner insider profile FAQ
What is the percentage of profitable transactions made by Mark Eisner?
The percentage of profitable transactions made by Mark Eisner is 100%.
What is the average return per transaction made by Mark Eisner?
The average return per transaction made by Mark Eisner is 80.40%.
What stocks does Mark Eisner hold?
Mark Eisner holds: FGEN, VIR stocks.
What was Mark Eisner’s latest transaction?
Mark Eisner latest transaction was an Uninformative Sell of $19.62K.
What was Mark Eisner's most profitable transaction?
Mark Eisner’s most profitable transaction was an Informative Sell of FGEN stock on June 5, 2023. The return on the trade was 93.60%.
What is Mark Eisner's role in FibroGen?
Mark Eisner's role in FibroGen is EVP, Chief Medical Officer.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.